Program in Evidence-based Care
Full Text Guideline
Evidence Supporting the Recommendations
Most of the recommendations were brought forward from the 2009 Recommendations Report (Stem cell transplantation in adults). New evidence in this report included randomized trials, prospective cohort studies, retrospective cohort studies, systematic reviews with or without meta-analysis, and clinical practice guidelines.
Implementation of the Guideline
An implementation strategy was not provided.
Benefits/Harms of Implementing the Guideline Recommendations
Improved overall survival, progression-free survival, and event-free survival
Stem cell transplantation is associated with toxicity including graft-versus-host disease (GVHD) and treatment-related mortality.
Rating Scheme for the Strength of the Recommendations
- The patient selection process and the ultimate decision to perform a stem cell transplant should take into account not only disease-related characteristics, but also co-morbidities and patient preferences.
- Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind whatsoever regarding the report content or use or application and disclaims any responsibility for its application or use in any way.
Searches of Electronic Databases
This Recommendation Report was created to update the 2009 Stem Cell Transplantation in Adults report. Using the Recommendations in that report as a starting point, evidence published from the original report's literature search dates to current was performed to gather the most evidence.
Literature Search Strategy
The MEDLINE (OVID) database (2006 through February [week three] 2011) was systematically searched for evidence on March 1, 2011 using the strategy that appears in Appendix A in the original guideline document. A total of 634 hits were obtained, and after excluding irrelevant papers according to a title and abstract review, 30 were ordered for full-text review. Of these 30 ordered for full-text review, 14 met the inclusion criteria and were retained.
Study Selection Criteria
Articles were selected based on the following criteria:
- Systematic reviews with or without meta-analysis or clinical practice guidelines if evidence was obtained with systematic review.
- Fully published randomized controlled trials (RCTs) on patients with lymphoma that received stem cell transplantation (SCT) and reported on survival and/or quality of life (QoL).
- Fully published non-randomized studies on patients with lymphoma that received SCT and had an appropriate contemporaneous control group that reported on survival or QoL.
- Reports published in English only.
Of the 30 papers ordered for full-text review, 14 met the inclusion criteria and were retained.
Expert Consensus (Committee)
Review of Published Meta-Analyses
Systematic Review with Evidence Tables
Synthesizing the Evidence
No pooling was planned for this report but would be considered if data allow.
Assessment of Study Quality
The quality of the included evidence was assessed as follows: For systematic reviews that would be used as the evidence base for the recommendations, the measurement tool to assess systematic reviews (AMSTAR) tool was used to assess quality. For clinical practice guidelines, the Appraisal of Guidelines for Research and Evaluation (AGREE) 2 instrument was used, but only if adaptation of the recommendations was being considered. Any meta-analysis was assessed for quality using similar criteria as used for randomized controlled trials (RCTs), where appropriate. RCTs were assessed for quality by examining the following seven criteria: the method of randomization, reporting of blinding, the power and sample size calculation, length of follow-up, reporting details of the statistical analysis, reporting on withdrawals to treatment and other losses to follow-up, and reporting on the sources of funding for the research. Comparative, but non-randomized, evidence was assessed according to full reporting of the patient selection criteria, the interventions each patient received and of all relevant outcomes.
A formal cost analysis was not performed and published cost analyses were not reviewed.
Identifying Information and Availability
Kouroukis CT, Rumble RB, Kuruvilla J, Crump M, Herst J, Hamm C. Stem cell transplantation in lymphoma. Toronto (ON): Cancer Care Ontario; 2012 Dec 13. 23 p. (Recommendation report; no. SCT-4). [28 references]
Not applicable: The guideline was not adapted from another source.
The Program in Evidence-based Care (PEBC) is a Province of Ontario initiative sponsored by Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care.
The Program in Evidence-Based Care (PEBC) is supported by Cancer Care Ontario (CCO) and the Ontario Ministry of Health and Long-Term Care. All work produced by the PEBC is editorially independent from its funding agencies.
Stem Cell Transplant Steering Committee
Primary Authors: Dr. C. Tom Kouroukis, Mr. R. Bryan Rumble, Dr. John Kuruvilla, Dr. Michael Crump, Dr. Jordan Herst, and Dr. Caroline Hamm
The authors reported on potential conflicts of interest relating to the topic, and none were declared.
This is the current release of the guideline.
This guideline updates a previous version: Imrie K, Rumble RB, Crump M, Advisory Panel on Bone Marrow and Stem Cell Transplantation, Hematology Disease Site Group. Stem cell transplantation in adults: recommendations. Toronto (ON): Cancer Care Ontario Program in Evidence-based Care; 2009 Jan 30. 78 p. (Recommendation report; no. 1).
The RECOMMENDATION REPORT, initially the full original Guideline, over time will expand to contain new information emerging from their reviewing and updating activities.
Please visit the Cancer Care Ontario Web site for details on any new evidence that has emerged and implications to the guidelines.
Electronic copies: Available from the Cancer Care Ontario Web site.
The following is available:
- Program in evidence-based care handbook. Toronto (ON): Cancer Care Ontario (CCO); 2011. 15 p. Available in Portable Document Format (PDF) from the Cancer Care Ontario Web site.
This summary was completed by ECRI Institute on February 12, 2010. This summary was updated by ECRI Institute on April 23, 2013.
This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions. Please refer to the Copyright and Disclaimer Statements posted at the Program in Evidence-based Care section of the Cancer Care Ontario Web site.
Lymphomas that may require stem cell transplantation, including:
- Hodgkin's lymphoma (HL)
- Non-Hodgkin's lymphomas
- Aggressive histology non-Hodgkin's lymphoma (NHL) including diffuse large B-cell lymphoma, transformed lymphoma, and aggressive histology T-cell lymphomas (AH-NHL)
- Follicular lymphoma (FL)
- Burkitt's lymphoma
- Mantle cell lymphoma (MCL)
Assessment of Therapeutic Effectiveness
- To evaluate the role of stem cell transplantation in the treatment of the various lymphomas
- To review the most-current evidence comparing treatment modalities that include a stem cell transplantation component, and to make a series of clinical recommendations to inform clinicians, patients and other stakeholders of the treatment options available
- To update the 2009 Stem Cell Transplantation in Adults report
All adult patients with lymphoma who are being considered for treatment that includes either bone marrow or stem cell transplantation
- Allogeneic stem cell transplantation
- Autologous stem cell transplantation
- Survival (overall, progression-free, event-free)
- Neutrophil engraftment
- Graft-versus-host disease
- Treatment-related mortality
Hodgkin's Lymphoma (HL)
- Stem cell transplantation is not recommended as part of routine primary therapy for HL. Standard treatment for HL remains chemotherapy with or without radiation.
- Autologous stem cell transplantation (ASCT) is the recommended treatment option for chemo-sensitive patients with HL who are refractory to or who have relapsed after primary chemotherapy. Patients with stable disease following salvage chemotherapy could also remain eligible for autologous stem cell transplantation. Patients with progressive disease despite salvage chemotherapy should not be offered autologous stem cell transplantation outside the context of a clinical trial.
- Allogeneic stem cell transplantation is an option for chemo-sensitive patients with refractory or relapsed HL if they have a syngeneic (identical twin) donor, following autologous stem cell transplantation failure, or alternatively in patients in whom sufficient numbers of autologous stem cells cannot be collected.
Non-Hodgkin's Lymphomas (NHL)
Aggressive Histology NHL Including Diffuse Large B-Cell Lymphoma, Transformed Lymphoma and Aggressive Histology T-Cell Lymphomas (AH-NHL)
- Autologous stem cell transplantation is the recommended option for chemo-sensitive patients with AH-NHL refractory to or relapsed after primary therapy.
- Allogeneic stem cell transplantation is an option for chemo-sensitive patients with refractory or relapsed NHL if they have a syngeneic (identical twin) donor, following autologous stem cell transplantation failure, or alternatively in patients in whom sufficient numbers of autologous stem cells cannot be collected.
- Stem cell transplantation is not recommended for patients with AH-NHL as part of primary therapy.
Follicular Lymphoma (FL)
- Autologous or allogeneic transplantation are options for chemo-sensitive patients with poor prognosis FL refractory to or relapsed after primary therapy.
- Autologous and allogeneic transplantation are options for chemo-sensitive patients with Burkitt's lymphoma refractory to or relapsed after primary treatment.
Mantle Cell Lymphoma (MCL)
- Autologous stem cell transplantation is recommended for patients with MCL in first remission.
- Select patients with MCL in first or second remission may be considered for allogeneic transplant. Autologous transplantation is also an option for chemo-sensitive patients with MCL in second remission.
Institute of Medicine (IOM) National Healthcare Quality Report Categories
Living with Illness
The National Guideline Clearinghouseâ¢ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.
All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.
Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at http://www.guideline.gov/about/inclusion-criteria.aspx.
NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.
Readers with questions regarding guideline content are directed to contact the guideline developer.